Search research articles
Contact Us
Filters
Showing results (101-110 of 129) with videos related to
Page
of 13
Sort By:
British Journal of Haematology
|
July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2006
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma
John D Roberts, Mitchell R Smith, Eric J Feldman, et al.
Journal of the National Cancer Institute
|
January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma
Stephen E Spurgeon, Brian G Till, Peter Martin, et al.
British Journal of Haematology
|
November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Thomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Cancer Research
|
May 20, 2016
Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Sergei Vatolin, James G Phillips, Babal K Jha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905
Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2015
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Jatin J Shah, Andrzej J Jakubowiak, Owen A O'Connor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2012
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma
Andres Forero-Torres, Sven de Vos, Brad L Pohlman, et al.
Blood
|
August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997
Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 7, 2017
Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience
Yazeed Sawalha, Brian T Hill, Lisa A Rybicki, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 129) with videos related to
Sort By:
Page
of 13
British Journal of Haematology
|
July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2006
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma
John D Roberts, Mitchell R Smith, Eric J Feldman, et al.
Journal of the National Cancer Institute
|
January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma
Stephen E Spurgeon, Brian G Till, Peter Martin, et al.
British Journal of Haematology
|
November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Thomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Cancer Research
|
May 20, 2016
Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma
Sergei Vatolin, James G Phillips, Babal K Jha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905
Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2015
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Jatin J Shah, Andrzej J Jakubowiak, Owen A O'Connor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2012
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma
Andres Forero-Torres, Sven de Vos, Brad L Pohlman, et al.
Blood
|
August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997
Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 7, 2017
Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience
Yazeed Sawalha, Brian T Hill, Lisa A Rybicki, et al.
Page
of 13